EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

IGF1 as a Potential Treatment for Rett Syndrome: Safety Assessment in Six Rett Patients

Giorgio Pini, Maria Flora Scusa, Laura Congiu, Alberto Benincasa, Paolina Morescalchi, Ilaria Bottiglioni, Pietro Di Marco, Paolo Borelli, Ubaldo Bonuccelli, Andrea Della-Chiesa, Adriele Prina-Mello, Daniela Tropea

Autism Research and Treatment · 2012 · 2012 · 1-14

DOI: 10.1155/2012/679801 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Autism Research and Treatment, 2012. Verfasst von Giorgio Pini und 11 weiteren Autor:innen. Beteiligte Einrichtung: Tuscany Rett Center, Versilia Hospital, 55043 Lido di Camaiore, Italy. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: Region Tuscany, ASL12 Viareggio, TIAMO Foundation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rett syndrome (RTT) is a devastating neurodevelopmental disorder that affects one in ten thousand girls and has no cure. The majority of RTT patients display mutations in the gene that codes for the methyl-CpG-binding protein 2 (MeCP2). Clinical observations and neurobiological analysis of mouse models suggest that defects in the expression of MeCP2 protein compromise the development of the central nervous system, especially synaptic and circuit maturation. Thus, agents that promote brain development and synaptic function, such as insulin-like growth factor 1 (IGF1), are good candidates for ameliorating the symptoms of RTT. IGF1 and its active peptide, (1–3) IGF1, cross the blood brain barrier, and (1–3) IGF1 ameliorates the symptoms of RTT in a mouse model of the disease; therefore they are ideal treatments for neurodevelopmental disorders, including RTT. We performed a pilot study to establish whether there are major risks associated with IGF1 administration in RTT patients. Six young girls with classic RTT received IGF1 subcutaneous injections twice a day for six months, and they were regularly monitored by their primary care physicians and by the unit for RTT in Versilia Hospital (Italy). This study shows that there are no risks associated with IGF1 administration.

Autor:innen und Institutionen

  • Tuscany Rett Center, Versilia Hospital, 55043 Lido di Camaiore, Italy.

Förderung

  • Region Tuscany
  • ASL12 Viareggio
  • TIAMO Foundation
  • Marie Curie IRG

Zitieren

APA

Pini, G., Scusa, M. F., Congiu, L., Benincasa, A., Morescalchi, P., Bottiglioni, I., Di Marco, P., Borelli, P., Bonuccelli, U., Della-Chiesa, A., Prina-Mello, A., & Tropea, D. (2012). IGF1 as a Potential Treatment for Rett Syndrome: Safety Assessment in Six Rett Patients. Autism Research and Treatment, 2012, 1-14. https://doi.org/10.1155/2012/679801

Vancouver

Pini G, Scusa MF, Congiu L, Benincasa A, Morescalchi P, Bottiglioni I, et al. IGF1 as a Potential Treatment for Rett Syndrome: Safety Assessment in Six Rett Patients. Autism Research and Treatment. 2012;2012:1-14. doi:10.1155/2012/679801

BibTeX
@article{Pini2012,
  author = {Pini, Giorgio and Scusa, Maria Flora and Congiu, Laura and Benincasa, Alberto and Morescalchi, Paolina and Bottiglioni, Ilaria and Di Marco, Pietro and Borelli, Paolo and Bonuccelli, Ubaldo and Della-Chiesa, Andrea and Prina-Mello, Adriele and Tropea, Daniela},
  title = {IGF1 as a Potential Treatment for Rett Syndrome: Safety Assessment in Six Rett Patients},
  journal = {Autism Research and Treatment},
  year = {2012},
  volume = {2012},
  pages = {1--14},
  doi = {10.1155/2012/679801}
}
Kostenlos starten →